Microbot Medical Inc
MBOT
查看详细走势图
1.760USD
+0.140+8.64%
收盘 02/06, 16:00（美东）报价延迟15分钟
115.87M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+8.64%
5天
-2.22%
1月
-19.63%
6月
-39.73%
今年开始到现在
-12.00%
1年
-30.98%
查看详细走势图
TradingKey Microbot Medical Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Microbot Medical Inc当前公司基本面数据相对谨慎，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名149/392位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价7.50。中期看，股价处于下降通道。近一个月，市场表现非常差，但技术面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Microbot Medical Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看空
Microbot Medical Inc亮点
亮点风险
Microbot Medical Inc. is a pre-commercial stage medical technology company. It has developed the single-use, fully disposable endovascular robotic system, which aims to eliminate traditional barriers to accessing advanced robotic systems. It specializes in the research, design and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. Using its LIBERTY technological platform, it is developing a fully disposable robot for various endovascular interventional procedures. The LIBERTY Endovascular Robotic Surgical System is designed to maneuver guidewires and over-the-wire devices (such as microcatheters) within the body’s vasculature. It eliminates the need for extensive capital equipment requiring dedicated Cath-lab rooms as well as dedicated staff. Its addressable markets for the LIBERTY Endovascular Robotic Surgical System include the peripheral interventional radiology, interventional cardiology and interventional neuroradiology markets.
估值低估
公司最新PE估值-3.91，处于3年历史低位
机构加仓
最新机构持股10.55M股，环比增加28.94%
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值3.33M
活跃度增加
近期活跃度增加，过去20天平均换手率-0.02
分析师目标
根据
2
位分析师
买入
评级
7.500
目标均价
+331.03%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Microbot Medical Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Microbot Medical Inc简介
Microbot Medical Inc. is a pre-commercial stage medical technology company. It has developed the single-use, fully disposable endovascular robotic system, which aims to eliminate traditional barriers to accessing advanced robotic systems. It specializes in the research, design and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. Using its LIBERTY technological platform, it is developing a fully disposable robot for various endovascular interventional procedures. The LIBERTY Endovascular Robotic Surgical System is designed to maneuver guidewires and over-the-wire devices (such as microcatheters) within the body’s vasculature. It eliminates the need for extensive capital equipment requiring dedicated Cath-lab rooms as well as dedicated staff. Its addressable markets for the LIBERTY Endovascular Robotic Surgical System include the peripheral interventional radiology, interventional cardiology and interventional neuroradiology markets.
公司代码MBOT
公司Microbot Medical Inc
CEOGadot (Harel)
网址http://www.microbotmedical.com/
相关品种
